Now Is The Time To Buy Maravai LifeSciences Holdings Inc (NASDAQ: MRVI)

During the last session, Maravai LifeSciences Holdings Inc (NASDAQ:MRVI)’s traded shares were 5.35 million, with the beta value of the company hitting 0.01. At the end of the trading day, the stock’s price was $8.61, reflecting an intraday gain of 1.18% or $0.1. The 52-week high for the MRVI share is $16.62, that puts it down -93.03 from that peak though still a striking 47.5% gain since the share price plummeted to a 52-week low of $4.52. The company’s market capitalization is $1.14B, and the average intraday trading volume over the past 10 days was 2.97 million shares, and the average trade volume was 2.71 million shares over the past three months.

Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) trade information

Maravai LifeSciences Holdings Inc (MRVI) registered a 1.18% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.18% in intraday trading to $8.61, hitting a weekly high. The stock’s 5-day price performance is 3.24%, and it has moved by 13.14% in 30 days. Based on these gigs, the overall price performance for the year is -38.54%. The short interest in Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) is 7.35 million shares and it means that shorts have 1.9 day(s) to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Maravai LifeSciences Holdings Inc (MRVI) estimates and forecasts

Statistics show that Maravai LifeSciences Holdings Inc has underperformed its competitors in share price, compared to the industry in which it operates. Maravai LifeSciences Holdings Inc (MRVI) shares have gone down -11.15% during the last six months, with a year-to-date growth rate less than the industry average at -133.33% against 17.50. In the rating firms’ projections, revenue will decrease -5.80% compared to the previous financial year.

Revenue for the current quarter is expected to be $60.55 million as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to $66.95 million by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $79.03 million and $68.91 million respectively. In this case, analysts expect current quarter sales to shrink by -23.40% and then drop by -2.80% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -37.53%. While earnings are projected to return -154.23% in 2024.

MRVI Dividends

Maravai LifeSciences Holdings Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Maravai LifeSciences Holdings Inc (NASDAQ:MRVI)’s Major holders

Maravai LifeSciences Holdings Inc insiders own 2.37% of total outstanding shares while institutional holders control 102.61%, with the float percentage being 105.10%. GTCR, LLC is the largest shareholder of the company, while 307 institutions own stock in it. As of Jun 29, 2023, the company held over 21.68 million shares (or 16.43% of all shares), a total value of $269.5 million in shares.

The next largest institutional holding, with 11.15 million shares, is of Massachusetts Financial Services Co.’s that is approximately 8.46% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $138.65 million.

Also, the Mutual Funds coming in first place with the largest holdings of Maravai LifeSciences Holdings Inc (MRVI) shares are Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 3.51 million shares. This amounts to just over 2.66 percent of the company’s overall shares, with a $43.63 million market value. The same data shows that the other fund manager holds slightly less at 2.89 million, or about 2.19% of the stock, which is worth about $35.98 million.